CN108358953B

CN108358953B - Copper and imidazopyridine compound complex and application thereof

Info

Publication number: CN108358953B
Application number: CN201810186452.1A
Authority: CN
Inventors: 胡春; 张雅馨; 高迪; 欧阳贵平; 常楚晴; 陈固洲; 王婧; 黎晓丹; 王菲
Original assignee: Shenyang Pharmaceutical University
Current assignee: Shenyang Pharmaceutical University
Priority date: 2018-03-07
Filing date: 2018-03-07
Publication date: 2020-07-03
Anticipated expiration: 2038-03-07
Also published as: CN108358953A

Abstract

The invention relates to a novel copper complex, namely a complex of copper and imidazopyridine compounds, a composition containing the complex and application of the complex in preparing an anti-tumor medicament. The structure of the compound of the invention is shown as the following formula: wherein R is₁Selected from H, C1-C6 alkyl, C1-C6 alkoxy; r₂Selected from H, substituted or unsubstituted C1-C6 alkyl, C1-C6 alkoxy; the substituent is C1-C6 alkoxy, C1-C6 alkyl and halogenated C1-C6 alkoxy; r₃Selected from H, C1-C6 alkyl, C1-C6 alkoxy. The complex of copper and imidazopyridine compounds and the composition thereof can be used for preparing antitumor drugs.

Description

Copper and imidazopyridine compound complex and application thereof

Technical Field

The invention relates to a novel copper complex, namely a complex of copper and imidazopyridine compounds, a composition containing the complex and application of the complex in preparing an anti-tumor medicament.

Background

Malignant tumors are one of the most serious diseases recognized in the world as being harmful to human health, and the harm is second to cardiovascular diseases. Therefore, the research of tumor treatment is enhanced, the effect of the existing various treatment means is improved, the cancer death rate is reduced, the recurrence rate is reduced, the life quality of cancer patients is improved, and the method has important social benefit and huge economic benefit. In tumor therapy, chemotherapy is one of the important methods for current tumor therapy. Among the chemotherapeutic drugs, platinum group compounds are a class of drugs with strong antitumor effect and wide antitumor spectrum. Since cisplatin (cispinin) was found to have antitumor activity by Rosenberg et al in 1967, it has been widely used as a highly potent antitumor agent for the treatment of various cancers such as testicular cancer, ovarian cancer, cervical cancer, bladder cancer, lung cancer, and head and neck cancer, etc. (Wong E, Giandomenic CM. Current status of planar-based anticancer or drugs. chem Rev,1999,99(9): 2451-2466.). Subsequently, a series of platinum compounds such as carboplatin (carboplatin), nedaplatin (nedaplatin), oxaliplatin (oxaliplatin), loplatin (lobaplatin), and cycloplatin (cycloplatin) have been successfully used clinically as antitumor metal drugs (Abu-SurrahAS, Ketton M. platinum group anticancer chemistry: design and development of new anticancer drugs to cancer. Current Med Chem,2006,13(11): 1337-57), but development of novel transition metal complex antitumor drugs is also drawing attention due to problems such as toxicity and drug resistance of platinum group compounds.

Meanwhile, copper, which is an essential trace element for biology, exists in the active sites of metalloproteins and metalloenzymes in the living body, and participates in maintaining normal physiological functions in the living body, has important effects on the development of hematopoietic system and central nervous system, the formation of bone and connective tissue, the deposition of skin pigment, etc., and has unique catalytic effect in the oxidation-reduction system in living organisms, plays a key role in the aging and cancer and DNA damage caused by endogenous oxidants associated with the cancer (Wang Feili, everbright, Anlihu, etc. research progress of non-platinum metal anti-cancer compounds, chemical research and application, 2003,15(5): 612. 616.), and the toxicity of copper is less than that of non-essential trace elements such as platinum, therefore, the copper metal complex is expected to maintain the antitumor activity of the platinum group compound and has the characteristic of low toxicity.

On the basis of synthesizing some benzimidazole compounds containing pyridine groups, the benzimidazole compounds are used as ligands to synthesize a series of complexes of copper and imidazopyridine compounds, and the complexes have remarkable antitumor activity and are expected to become novel candidate drugs for antitumor treatment.

Disclosure of Invention

The invention aims to provide a compound shown as a formula I, a prodrug, a pharmaceutically active metabolite and a pharmaceutically acceptable salt thereof, and provides application of the compound in preparation of antitumor drugs.

The structure of the compound of the invention is shown as the following formula (I):

wherein,

R₁selected from H, C1-C6 alkyl, C1-C6 alkoxy;

R₂selected from H, substituted or unsubstituted C1-C6 alkyl, C1-C6 alkoxy; the substituent is C1-C6 alkoxy, C1-C6 alkyl and halogenated C1-C6 alkoxy;

R₃selected from H, C1-C6 alkyl, C1-C6 alkoxy.

Preferably, the first and second electrodes are formed of a metal,

R₁selected from H, C1-C4 alkyl, C1-C4 alkoxy;

R₂selected from H, substituted or unsubstituted C1-C4 alkyl, C1-C4 alkoxy; the substituent is C1-C4 alkoxy, C1-C4 alkyl and halogenated C1-C4 alkoxy;

R₃selected from H, C1-C4 alkyl, C1-C4 alkoxy.

Further, the air conditioner is provided with a fan,

R₁selected from H, methyl, methoxy;

R₂selected from H, methyl, methoxy, 2-methoxyethoxy, 3-methoxypropoxy, 2,2, 2-trifluoroethoxy;

R₃selected from H, methyl and methoxy.

The term "pharmaceutically acceptable salt" refers to conventional acid addition salts or base addition salts which retain the biological effectiveness and properties of the compounds of formula I and which are formed with suitable non-toxic organic or inorganic acids or organic or inorganic bases, the acid addition salts include hydrochloride, hydrobromide, hydroiodide, nitrate, phosphate, sulfate, perchlorate, thiocyanate, bisulfate, persulfate, borate, formate, acetate, propionate, valerate, pivalate, hexanoate, heptanoate, octanoate, isooctanoate, undecanoate, laurate, palmitate, stearate, oleate, cycloproponate, oxalate, malonate, succinate, maleate, fumarate, adipate, azelate, acrylate, strawberry, crotonate, tiglate, itaconate, sorbate, cinnamate, glycolate, malate, tartrate, citrate, tartrate, mandelate, prolinate, ascorbyl, gluconate, glucarate, mannitol, maleate, tartrate, phenazinate, phenalenoate, cinnamate.

"pharmaceutically acceptable" such as pharmaceutically acceptable carriers, excipients, prodrugs, etc., means pharmacologically acceptable and substantially non-toxic to a patient to whom a particular compound is administered.

"pharmaceutically active metabolite" refers to a pharmaceutically acceptable and effective metabolite of a compound of formula I.

The invention also relates to pharmaceutical compositions comprising formula I or a stereoisomer thereof or a pharmaceutically acceptable acid addition salt thereof, in combination with a pharmaceutically acceptable carrier.

Certain crystalline forms of the compounds may exist as polymorphs and as such are included in the present invention. In addition, some compounds may form solvates with water (i.e., hydrates) or common organic solvents, and such solvates are also within the scope of the present invention.

The present invention includes within its scope prodrugs of the compounds of the present invention. In general, such prodrugs will be functional derivatives of the present compounds that are readily converted in vivo to the desired compound. Thus, in the methods of treatment of the present invention, the term "administering" shall encompass the treatment of the various described conditions with a compound specifically disclosed, or with a compound that is not specifically disclosed but which converts to the specified compound in vivo in the patient upon administration.

The following reaction scheme outlines the preparation steps for preparing the compounds of the present invention.

Reaction scheme

The invention also relates to a complex of copper and imidazopyridine compounds for treating tumors as an anti-tumor medicament.

Methods of treatment and dosages used

The various diseases and conditions to be treated described herein are well known and clear to those skilled in the art. It is also understood that one skilled in the art can treat a patient currently afflicted with a disease or condition with a therapeutically effective amount of the compound or affect the disease or condition by prophylactically treating a patient afflicted with a disease or condition.

The term "patient" as used herein refers to a warm-blooded animal, such as a mammal, having a tumor. It is understood that guinea pigs, dogs, cats, rats, mouse horses, cattle, sheep, and humans are examples of animals within the meaning of the term.

The term "therapeutically effective amount" as used herein refers to an amount effective for the control of tumor-associated diseases and conditions. The term "controlling" is intended to refer to all processes by which the progression of the diseases and conditions described herein can be slowed, interrupted, arrested or halted, and not necessarily the complete elimination of all of the symptoms of the disease and condition.

A therapeutically effective amount can be readily determined by the attending diagnostician as one skilled in the art using routine techniques and observing results obtained under analogous circumstances. In determining a therapeutically effective amount of a dosage, the attending diagnostician considers a number of factors, including but not limited to: the species of mammal; its size, age and general health; the specific diseases involved; the degree or complexity or severity of the disease; the response of the individual patient; the particular compound administered; the mode of administration; bioavailability characteristics of the administered formulation; a selected dosing regimen; concomitant medication use and other related conditions.

Therapeutically effective amounts of the compounds are expected to vary from about 0.001 milligrams per kilogram of body weight per day (mg/kg/day) to about 100 mg/kg/day. Preferred amounts can be determined by one skilled in the art.

In effectively treating patients suffering from the diseases and conditions described above, such compounds may be administered in any form or manner that makes the compound bioavailable in therapeutically effective amounts, including oral, inhaled, and parenteral routes. For example, the compounds can be administered orally, by inhalation as an aerosol or dry powder, by subcutaneous injection, intramuscular injection, intravenous injection, transdermal administration, intranasal administration, rectal administration, topical administration, and the like. Oral or inhalation administration is generally preferred for the treatment of respiratory diseases such as asthma. One skilled in the art of formulating formulations can readily select the appropriate form and mode of administration depending on the particular characteristics of the compound selected, the condition of the disease or condition to be treated, the stage of the disease or condition, and other relevant circumstances.

The compounds of the present invention may be administered alone or in combination with pharmaceutically acceptable carriers or excipients in the form of pharmaceutical compositions, the proportions and properties of which are determined by the solubility and chemical properties of the compound selected, the route of administration selected, and standard pharmaceutical practice. The compounds of the present invention, while effective per se, may be formulated and administered in the form of their pharmaceutically acceptable salts, such as acid or base addition salts, for the purposes of stability, ease of crystallization, improved solubility, and the like.

The present invention provides pharmaceutical compositions comprising a therapeutically effective amount of a compound admixed or otherwise associated with one or more pharmaceutically acceptable carriers or excipients.

The pharmaceutical compositions are prepared according to methods well known in the pharmaceutical art. The carrier or excipient which may serve as a vehicle or medium for the active ingredient may be a solid, semi-solid, or liquid material. Suitable carriers or excipients are well known in the art. The pharmaceutical compositions may be adapted for oral, inhalation, parenteral or topical use and may be administered to the patient in the form of tablets, capsules, aerosols, inhalants, suppositories, solutions, suspensions and the like.

The compounds of the present invention may be administered orally, for example, with an inert diluent or with an edible carrier, which may be enclosed in capsules or compressed into tablets. For oral therapeutic administration, the compounds may be incorporated with excipients and used in the form of tablets, troches, capsules, elixirs, suspensions, syrups, wafers, chewing gums and the like. These formulations should contain at least 4% of the compound of the invention, i.e. the active ingredient, but may vary depending on the particular form, conveniently between 4% and about 70% by weight of the unit. The amount of the compound present in the composition should be such that a suitable dosage is obtained. Preferred compositions and formulations of the present invention may be determined by one skilled in the art.

The tablets, pills, capsules, lozenges and the like may further contain one or more of the following adjuvants: binders such as microcrystalline cellulose, gum tragacanth or gelatin; excipients such as starch or lactose, disintegrants such as alginic acid, Primogel, corn starch and the like; lubricants such as magnesium stearate or Sterotex; glidants such as colloidal silicon dioxide; and a sweetening agent such as sucrose or saccharin may be added or a flavoring agent such as peppermint, methyl salicylate, or orange flavoring. When the dosage unit form is a capsule, it may contain, in addition to materials of the above type, a liquid carrier such as polyethylene glycol or a fatty oil. Other dosage unit forms may contain other, different materials that modify the physical form of the dosage unit, for example as a coating. Syrups, in addition to containing the compound, may contain sucrose as a sweetening agent and certain preservatives, dyes and colorings and flavors. The materials used in preparing these various compositions should be pharmaceutically pure and non-toxic in the amounts used.

For parenteral administration, the compounds of the invention may be added to a solution or suspension. These formulations should contain at least 0.1% of the compound of the invention, but may vary between 0.1 and about 50% by weight of the formulation. The amount of compound present in such compositions should be such that a suitable dosage is obtained. Preferred compositions and vitex negundo can be determined by a person skilled in the art.

The compounds of the invention may also be administered by inhalation, for example as an aerosol or dry powder. May be released by a liquefied or compressed gas or by a suitable pumping system which dispenses the compounds of the invention or their formulations. Formulations for administration by inhalation of the compounds may be delivered in monophasic, biphasic or triphasic systems. For aerosol administration of the compounds, a number of systems are available. Dry powder formulations are prepared by granulating or milling the compound to the appropriate particle size or by mixing the granulated or milled compound with a suitable carrier, such as lactose or the like. Delivery systems by inhalation include the necessary containers, active agents, valves, sub-containers, and the like. Preferred aerosol and dry powder formulations for administration by inhalation can be determined by one skilled in the art.

The compounds of the invention may also be administered topically, in which case the carrier will suitably comprise a solution, ointment or gel base. The base may, for example, contain one or more of the following substances: petrolatum, lanolin, polyethylene glycols, beeswax, mineral oil, diluents such as water and alcohol, and emulsifiers and stabilizers. The concentration of the calcium-containing compound or pharmaceutically acceptable salt thereof in the topical formulation may be from about 0.1 to about 10% w/v (weight per unit volume).

The solution or suspension may also contain one or more of the following adjuvants: sterile diluents such as water for injection, saline solution, fixed oils, polyethylene glycols, glycerin, propylene glycol or other synthetic solvents; antibacterial agents such as benzyl alcohol or methyl paraben; antioxidants such as vitamin C or sodium bisulfite; chelating agents such as ethylenediaminetetraacetic acid; buffers such as acetates, citrates or phosphates and agents for adjusting the osmotic pressure such as sodium chloride or glucose. The parenteral formulations may be presented in ampoules, disposable syringes or multiple dose vials made of glass or plastic.

Detailed Description

Example 1: bis (. mu. -sulfate-O, O') bis { 5-methoxy-2- [ (3, 4-dimethoxy-2-pyridyl) methylthio-kappa.N]-1H-imidazo [4,5-b]Pyridine-kappa N³Preparation of (II) bis (copper) (ZG-01)

After 1.27g (7.97mmol) of copper sulfate pentahydrate was completely dissolved in 30mL of methanol, 2- [ (3, 4-dimethoxy-2-pyridyl) methylthio group was added dropwise thereto]-1H-imidazo [4,5-b]Pyridine 2.40g (7.97mmol) in 10mL methanol solution, reacting at room temperature overnight, detecting by TLC, after the reaction is completed, distilling off the methanol solution under reduced pressure to obtain a dark green solid with metallic luster, namely bis (mu-sulfate radical-O, O') bis { 5-methoxy-2- [ (3, 4-dimethoxy-2-pyridyl) methylthio-kappa N]-1H-imidazo [4,5-b]Pyridine-kappa N³The yield of the product was 100.0%. m.p:>250℃；HRMS:980.947355([M-H]^-)；IR:3426.5,2928.6,2169.7,1696.9,1460.3,1391.1,1353.2,1312.2,1220.1,1118.2,1073.4,1022.0,863.9,772.8。

example 2: bis (. mu. -sulfate-O, O') bis { 5-methoxy-2- { [ 3-methyl-4- (2,2, 2-trifluoroethyl) -2-pyridinyl]Methylthio-kappa N]-1H-imidazo [4,5-b]Pyridine-kappa N³Preparation of (II) bis (copper) (ZG-02)

Referring to the preparation method of example 1, dark green metallic lustrous powder was obtained with a yield of 100.0%. m.p:>250℃；HRMS:1024.913695([M-H]^-)；IR:3421.0,2923.9,1631.9,1602.3,1456.5,1339,1309.4,1276.0,1213.8,1106.5,1075,865.8,835.4。

example 3: bis (. mu. -sulfate-O, O') bis { 5-methoxy-2- [ (3-methyl-4-methoxy-2-pyridyl) methylsulfanyl-kappa.N]-1H-imidazo [4,5-b]Pyridine-kappa N³Preparation of (II) bis (copper) (ZG-03)

Referring to the preparation method of example 1, dark green metallic lustrous powder was obtained with a yield of 100.0%. m.p:>250℃；HRMS:948.981332([M-H]^-)；IR:3423.5,2923.9,2169.5,1696.6,1457.7,1394.6,1353.0,1273.4,1219.5,1088.3,1020.4,994.2,864.9。

example 4: bis (. mu. -sulfate-O, O') bis { 5-methoxy-2- [ (3, 5-dimethyl-4-methoxy-2-pyridyl) methylsulfanyl-. kappa.N]-1H-imidazo [4,5-b]Pyridine-kappa N³Preparation of (II) bis (copper) (ZG-04)

Referring to the preparation method of example 1, dark green metallic lustrous powder was obtained with a yield of 100.0%. m.p:>250℃；HRMS:1063.050545([M-H]^-)；IR:3427.4,2926.1,2169.6,1597.9,1460.3,1392.9,1354.4,1305.1,1222.9,1123.7,1095.9,1017.9,865.2,817.0。

example 5: inhibitory Activity of test Compounds on proliferation of human liver cancer cell HepG2, human colon cancer cell SW480 and human normal liver cell HL7702

(1) Experimental Material

Cell lines: human liver cancer cell HepG2, human colon cancer cell SW480, and human normal cancer cell HL 7702; 10% newborn bovine serum (FBS); a 96-well plate; dulbecco's Modified Eagle Medium (DMEM).

Test compounds: L-01-L-16, C-01-C-16 total 32 compounds, dissolved in DMSO to 50mM and stored at-20 ℃ for later use, with the final concentration of DMSO in the culture solution being less than 0.1%.

MTT test: dissolved in PBS at 5mg/mL and stored at-20 ℃.

(2) Experimental methods

The antitumor activity of the test compounds was determined by the MTT method (Mosmann T. Rapid clinical laboratory for cellular growth and efficacy: application to promotion and cytoxicity assays. J Immunol methods.1983,65(1-2): 55-63).

HepG2 (liver cancer), SW480 (human colon cancer) and HL7702 (human normal liver cells) were cultured on cell Eagle medium (DMEM) modified by Dulbecco's including 10% bovine serum (FBS), SW480 cell line and HepG2 cell line, each compound was administered to a final concentration of 50uM and 25uM in 3 parallel wells, and when the cells proliferated to 80-90%, they were pooled and then subcultured for no more than 20 passages, and then allowed to acclimate for 24h before the next treatment, and the cells were plated on 96-well plates (8 × 10)⁴/mL) and then in a solution containing 5% CO₂In a humid environment overnight and temperature controlledAt 37 ℃. After further culturing at 37 ℃ for 24h, adding MTT (5mg/ml) solution to each well, shaking the culture plate gently, putting the plate back into the incubator for further incubation for 4h, then sucking out the supernatant, adding 100. mu.L of DMSO to each well, shaking the plate on a shaker for 5-10 min to completely dissolve MTT, measuring the absorbance (OD value) at 490nm in each well by using an enzyme-linked immunosorbent assay (TECAN SPECTRA, Wetzlar, Germany), and calculating the inhibition ratio according to the following formula (see Table 1).

Inhibition (1-drug OD/control OD) × 100%

Cisplatin is used as positive control drug, and IC of cisplatin for inhibiting proliferation of human liver cancer cell (HepG2) and human colon cancer cell (SW480)₅₀Respectively 6.6 +/-1.0 mu mol/L and 15 +/-2.7 mu mol/L.

Experimental results show that the tested copper complexes have different inhibition effects on the proliferation of human liver cancer cells HepG2 and show a dose-effect relationship, only a few tested copper complexes have the inhibition effects on the proliferation of human colon cancer cells SW480, the inhibition effects of the tested copper complexes on the proliferation of human liver cancer cells HepG2 are stronger than the inhibition effects on the proliferation of human colon cancer cells SW480, and the tested copper complexes have almost no inhibition effects on the proliferation of human normal liver cells HL 7702.

TABLE 1 inhibition of various cell proliferations by test Compounds

Pharmaceutical composition

Example 6: tablet formulation

25-1000mg of active compound, 45mg of starch, 35mg of microcrystalline cellulose, 4mL of polyvinylpyrrolidone (as a 10% aqueous solution), 4.5mg of sodium carboxymethylcellulose, 0.5mg of magnesium stearate, and 1mg of talc.

Example 7: suspending agent formula

0.1-1000mg of active compound, 50mg of sodium carboxymethylcellulose, 1.25mg of syrup, 0.1mg of sodium benzoate, a proper amount of flavoring agent and a proper amount of coloring agent, and adding pure water to 5 mL.

Example 8: aerosol formulations

0.25mg of active compound, 25-75mL of ethanol and 70mg of propellant 22 (chlorodifluoromethane).

Example 9: suppository formula

250mg of active compound, 2000mL of saturated fatty acid glycerides.

Example 10: injectable formulation

50mg of active compound, 1000mL of isotonic saline solution.

Example 11: ointment formulation

0.025g of micronized active compound, 10g of liquid paraffin, and 100g of soft white wax.

Example 12: ointment formulation

0.025g of active compound, 5g of propylene glycol, 5g of sorbitan sesquioleate, 10g of liquid paraffin and 100g of soft white wax.

Example 13: oil-in-water cream formulation

0.025g of active compound, 5g of cetyl alcohol, 5g of glycerol monostearate, 10g of liquid paraffin, 10002 g g of Ce tomacriol, 0.1g of citric acid, 0.2g of sodium citrate, 35g of propylene glycol and water to 100 g.

Example 14: oil-in-water cream formulation

0.025g of micronized active compound, 15g of soft white wax, 5g of liquid paraffin, 5g of cetyl alcohol, 2g of Sorbimcarol stearate, 0.5g of sorbitan monostearate, 0.2g of sorbic acid, 0.1g of citric acid, 0.2g of sodium citrate, and water to 100 g.

Example 15: water-in-oil cream formulation

0.025g of active compound, 35g of soft white wax, 5g of liquid paraffin, 5g of sorbitan sesquioleate, 0.2g of sorbic acid, 0.1g of citric acid and 0.2g of sodium citrate, and water is added until the weight is 100 g.

Example 16: lotion formulation

0.25g of active compound, 0.5mL of isopropanol, 3mg of carboxyvinyl polymer, a suitable amount of NaOH and water to 1 g.

Example 17: suspension formulation for injection

0.05-10mg of active compound, 7mg of sodium carboxymethylcellulose, 7mg of NaCl, 0.5mg of polyoxyethylene (20) sorbitan monooleate, 8mg of benzyl alcohol, and sterile water to 1 mL.

Example 18: aerosol formulation for oral and nasal inhalation

0.1% w/w active compound, 0.7% w/w sorbitan trioleate, 24.8% w/w trichlorofluoromethane, 24.8% w/w dichlorotetrafluoroethane and 49.6% w/w dichlorodifluoromethane.

Example 19: atomized solution formulation

7mg of active compound, 5mg of propylene glycol, water to 10 g.

Example 20: powder formulations for inhalation

Gelatine capsules were filled with a mixture of the following ingredients, micronised active compound 0.1mg, lactose 20mg and the powder was inhaled with the aid of an inhalation device.

Example 21: powder formulations for inhalation

The spheronized powder was loaded into a multi-dose powder inhaler containing 0.1mg of micronized active compound per dose.

Example 22: powder formulations for inhalation

The spheronized powder was loaded into a multi-dose powder inhaler containing 0.1mg of micronized active compound and 1mg of micronized lactose per dose.

Example 23: capsule formulation

1.0 part of active compound, 321mg of small sugar spheres, 306.6 mg of Aquacoat ECD, 0.5mg of acetyl tributyl citrate, 800.1 mg of Tween-800, 100-5517.5 mg of Eudragit L, 1.8mg of triethyl citrate, 8.8mg of talcum powder and 0.lmg of defoamer MMS.

Example 24: capsule seedling formula

2.0mg of active compound, 305mg of small sugar spheres, Aquocoat ECD 305.0 mg, acetyl tributyl citrate 0.4mg, Tween-800.14 mg, Eudragit NE 30D 12.6mg, Eudragit S10012.6 mg, talc 0.l6 mg.

Example 25: enema formula

00.2mg of active compound, 25mg of sodium carboxymethylcellulose, 0.5mg of disodium ethylenediaminetetraacetate, 0.8mg of methylparaben, 0.2mg of propylparaben, 7mg of sodium chloride, 1.8mg of citric acid, 800.01 mg of tween-800, and 1mL of pure water.

Example 26: formulations containing liposomes

A. Preparation of the instillation formulation

The synthesized dipalmitoyl lecithin (45mg), dimyristoyl lecithin (7mg), dipalmitoyl phosphatidylglycerol (1mg) and active compound (5mg) were mixed in a glass tube, and all components were dissolved in chloroform with N₂Adding an aqueous solution (0.9% NaCl) to the lipids, forming liposomes at a temperature above the phase inversion temperature of the lipids, the resulting suspension containing liposomes ranging in size from very small vesicles to 2 μm.

B. Preparation of formulations for inhalation

Liposomes were prepared as in example A, with an aqueous solution containing 10% lactose at a 7:3 lactose to lipid ratio. The liposome suspension was frozen with dry ice and freeze-dried, and the dried product was micronized, and the Mass Mean Aerodynamic Diameter (MMAD) of the resulting particles was about 2 μm.

The foregoing is directed to preferred embodiments of the present invention, other and further embodiments of the invention may be devised without departing from the basic scope thereof, and the scope thereof is determined by the claims that follow. Any simple modification, equivalent change and modification of the above embodiments according to the technical essence of the present invention, without departing from the technical solution of the present invention, still belong to the protection scope of the technical solution of the present invention.

Claims

1. A compound or pharmaceutically acceptable salt of formula (I):

wherein,

R₁selected from H, C1-C6 alkyl, C1-C6 alkoxy;

R₂selected from H, 2,2, 2-trifluoroethoxy, substituted or unsubstituted C1-C6 alkylC1-C6 alkoxy; the substituent is C1-C6 alkoxy, halogenated C1-C6 alkoxy;

R₃selected from H, C1-C6 alkyl, C1-C6 alkoxy.

2. The compound or pharmaceutically acceptable salt of claim 1, wherein,

R₁selected from H, C1-C4 alkyl, C1-C4 alkoxy.

3. The compound or pharmaceutically acceptable salt of claim 1, wherein,

R₁selected from H, methyl and methoxy.

4. The compound or pharmaceutically acceptable salt of any one of claims 1-3, wherein,

R₂selected from H, substituted or unsubstituted C1-C4 alkyl, C1-C4 alkoxy; the substituent is C1-C4 alkoxy and halogenated C1-C4 alkoxy.

5. The compound or pharmaceutically acceptable salt of any one of claims 1-3, wherein,

R₂selected from H, methyl, methoxy, 2-methoxyethoxy, 3-methoxypropoxy.

6. The compound or pharmaceutically acceptable salt of any one of claims 1-3, wherein,

R₃selected from H, C1-C4 alkyl, C1-C4 alkoxy.

7. The compound or pharmaceutically acceptable salt of any one of claims 1-3, wherein,

R₃selected from H, methyl and methoxy.

8. A compound or pharmaceutically acceptable salt of:

bis (. mu. -sulfate-O, O') bis { 5-methoxy-2- [ (3, 4-dimethoxy-2-pyridyl) methylthio ] methyl group]-1H-imidazo [4,5-b]Pyridine-kappa N³Copper (II) and (II);

bis (. mu. -sulfate-O, O') bis { 5-methoxy-2- { [ 3-methyl-4- (2,2, 2-trifluoroethyl) -2-pyridinyl]Methylthio-kappa N]-1H-imidazo [4,5-b]Pyridine-kappa N³Copper (II) and (II);

bis (. mu. -sulfate-O, O') bis { 5-methoxy-2- [ (3-methyl-4-methoxy-2-pyridyl) methylsulfanyl-kappa.N]-1H-imidazo [4,5-b]Pyridine-kappa N³Copper (II) and (II);

bis (. mu. -sulfate-O, O') bis { 5-methoxy-2- [ (3, 5-dimethyl-4-methoxy-2-pyridyl) methylsulfanyl-. kappa.N]-1H-imidazo [4,5-b]Pyridine-kappa N³And (II) bis-copper (II).

9. A pharmaceutical composition comprising as active ingredient a compound or pharmaceutically acceptable salt according to any one of claims 1 to 8 and a pharmaceutically acceptable carrier or excipient.

10. A process for preparing a compound or pharmaceutically acceptable salt according to claim 1,

11. use of a compound or pharmaceutically acceptable salt according to any one of claims 1 to 8 in the manufacture of a medicament for the treatment of tumours.

12. Use of the pharmaceutical composition of claim 9 for the preparation of a medicament for the treatment of tumors.

13. Use according to claim 12, characterized in that: the tumor is liver cancer, colon cancer or rectal cancer.